# Cetuximab in Combination With Anti-PD-1 and mFOLFOX Treat For RAS/BRAF wt Right-Sided Colon Cancer

> **NCT05468177** · PHASE2 · UNKNOWN · sponsor: **Tongji Hospital** · enrollment: 66 (estimated)

## Conditions studied

- Colonic Neoplasms

## Interventions

- **COMBINATION_PRODUCT:** neoadjuvant chemotherapy

## Key facts

- **NCT ID:** NCT05468177
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-01
- **Primary completion:** 2023-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2022-07-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05468177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05468177, "Cetuximab in Combination With Anti-PD-1 and mFOLFOX Treat For RAS/BRAF wt Right-Sided Colon Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05468177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*